# EDGAR Filing Document

**Accession Number:** 0001808158
**File Stem:** 0001193125-26-015507
**Filing Date:** 2026-1
**Character Count:** 17978
**Document Hash:** 2341c433e04bb77064a64d4e3f778ca1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-015507.hdr.sgml**: 20260116

**ACCESSION NUMBER**: 0001193125-26-015507

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260116

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260116

**DATE AS OF CHANGE**: 20260116

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Repare Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001808158
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39335
- **FILM NUMBER:** 26540356

**BUSINESS ADDRESS:**
- **STREET 1:** 7171 FREDERICK BANTING
- **STREET 2:** SUITE 270, BUILDING 2
- **CITY:** SAINT-LAURENT
- **STATE:** A8
- **ZIP:** H4S 1Z9
- **BUSINESS PHONE:** (857) 412-7018

**MAIL ADDRESS:**
- **STREET 1:** 7171 FREDERICK BANTING
- **STREET 2:** SUITE 270, BUILDING 2
- **CITY:** SAINT-LAURENT
- **STATE:** A8
- **ZIP:** H4S 1Z9

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): January 16, 2026

## Repare Therapeutics Inc.

#### (Exact Name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Québec** | **001-39335** | **Not applicable** |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission**<br>**File Number)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

---

| | |
|:---|:---|
| **7171 Frederick-Banting, Building 2, Suite 270** |  |
| **St-Laurent, Québec, Canada** | **H4S 1Z9** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's Telephone Number, Including Area Code: (857) 412-7018

#### Not Applicable

#### (Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol** | **Name of each exchange**<br>**on which registered** |
| Common shares, no par value | RPTX | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 5.07 Submission of Matters to a Vote of Security Holders
On January 16, 2026, Repare Therapeutics Inc., a corporation governed by the *Business Corporations Act* (Québec) (the "Company"), held a Special Meeting (the "Meeting") of the holders of the Company's shares (the "Common Shares," and the holders of such Common Shares, the "Shareholders"), at which a quorum was present. At the Meeting, the Company's Shareholders voted on the four proposals set forth below. A more detailed description of each proposal is set forth in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on December 15, 2025 (the "Proxy Statement").

#### Proposal 1 - The Arrangement
Pursuant to an order from the Superior Court of Québec (Commercial Division), dated as of December 10, 2025, to consider, and, if thought advisable, to pass, with or without variation, a special resolution (the "Arrangement Resolution") approving a plan of arrangement under Chapter XVI - Division II of the *Business Corporations Act* (Québec) (the "QBCA") involving the Company and Xeno Acquisition Corp., a company existing under the laws of Delaware (the "Purchaser"), whereby the Purchaser will, among other things, acquire all of the issued and outstanding Common Shares (as defined in the Proxy Statement) (the "Arrangement"). The Arrangement Resolution was approved by (i) 99.76% of the votes cast by Shareholders present in person or represented by proxy at the Meeting and (ii) 99.76% of the votes cast by Shareholders present in person or represented by proxy at the Meeting, excluding for this purpose the votes required to be excluded by Multilateral Instrument 61-101 - *Protection of Minority Security Holders in Special Transactions* ("MI 61-101"), which excludes common shares held by related parties that are receiving a "collateral benefit" (as defined in MI 61-101) in connection with the Arrangement. The votes cast were as follows:

*Shareholders* 

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstain** |
| 25954251 | 58162 | 4811 |

---

*Shareholders, excluding the votes that must be excluded pursuant to MI 61-101* 

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstain** |
| 25879894 | 58162 | 4811 |

---

#### Proposal 2 - The Compensation Resolution
An ordinary resolution to approve, on an advisory and non-binding basis, the compensation to be paid or become payable to the Company's named executive officers that is based on or otherwise relates to the Arrangement. The votes cast were as follows:

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstain** |
| 25846791 | 166117 | 4316 |

---

#### Proposal 3 - The Liquidation Resolution
In the event that the Arrangement Resolution is not approved or the Arrangement is otherwise terminated, to consider, and if thought advisable, to pass, with or without variation, a special resolution pursuant to Section 308 of the QBCA to approve the voluntary liquidation and dissolution of the Company in the event the Arrangement is terminated. The votes cast were as follows:

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstain** |
| 25951582 | 59405 | 6237 |

---

------

#### Proposal 4 - The Liquidator Resolution
In the event that the Arrangement Resolution is not approved or the Arrangement is otherwise terminated, and to consider, and if thought advisable, to pass, with or without variation, a special resolution pursuant to Section 325 of the QBCA to approve the appointment of KPMG LLP or, in the alternative, another liquidator of nationally recognized experience, as the liquidator of the Company with authorization for the board of directors of the Company to set the remuneration of the liquidator. The votes cast were as follows:

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstain** |
| 25951804 | 59820 | 5600 |

---

#### Item 7.01 Regulation FD Disclosure
On January 16, 2026, the Company issued a press release announcing the results of the voting at the Special Meeting. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

#### Item 9.01 Financial Statements and Exhibits
(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br>**No.** | **Description** |
| 99.1 | [Press Release dated January 16, 2026.](d14040dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **REPARE THERAPEUTICS INC.** | **REPARE THERAPEUTICS INC.** |
| By: | /s/ Steve Forte |
|  | Steve Forte |
|  | President, Chief Executive Officer and Chief Financial Officer |

---

Dated: January 16, 2026

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g14040g0116230625683.jpg)

**Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.** 

**CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE) – January 16, 2026 –** Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the "Common Shares" and the holders of the Common Shares, the "Shareholders") by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly "Xeno"), a non-profit biotechnology company, by way of a statutory plan of arrangement (the "Transaction" or the "Arrangement") at the special meeting of Shareholders held today (the "Meeting").

The special resolution approving the Arrangement was approved by: (i) 99.76% of the votes cast by Shareholders present in person or represented by proxy at the Meeting, and (ii) 99.76% of the votes cast by Shareholders, present in person or represented by proxy at the Meeting, excluding for this purpose the votes required to be excluded pursuant to *Multilateral Instrument 61- 101 – Protection of Minority Security Holders in Special Transactions*.

At the Meeting, Shareholders also approved: (a) on an advisory and non-binding basis, the compensation to be paid or become payable to the Company's named executive officers that is based on or otherwise relates to the Arrangement by 99.34% of the votes cast by Shareholders present in person or represented by proxy at the Meeting; and (b) in the event the Arrangement is terminated, (i) the voluntary liquidation and dissolution of the Company by 99.75% of the votes cast by Shareholders present in person or represented by proxy at the Meeting and (ii) the appointment of KPMG LLP or, in the alternative, another liquidator of nationally recognized experience, as the liquidator of the Company with authorization for the board of directors of the Company to set the remuneration of the liquidator by 99.75% of the votes cast by Shareholders present in person or represented by proxy at the Meeting.

The Arrangement is subject to the approval of the Superior Court of Québec (the "Court") and other customary closing conditions. The Court hearing for the final order to approve the Arrangement is expected to take place on January 23, 2026 and, assuming receipt of the approval of the Court and satisfaction of other customary conditions to closing, the completion of the Arrangement is expected to occur on or about January 28, 2026.

**About Repare Therapeutics Inc.** 

Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-1664, a Phase 1 PLK4 inhibitor. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.

**About XenoTherapeutics, Inc.** 

XenoTherapeutics, Inc. is a Massachusetts-based 501(c)(3) research foundation focused on advancing xenotransplantation through scientific research, clinical development, and public education. For more information, please visit www.xenotx.org.

------

**Forward Looking Statements** 

This news release contains certain information which, as presented, constitutes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable securities laws in Canada. All statements in this news release other than statements of historical facts are forward-looking statements and forward-looking information. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this news release include, but are not limited to, statements regarding: the proposed timing and completion of the Transaction; the timing and receipt of Court approval of the Transaction; the satisfaction of the conditions to the completion of the Transaction; and any other statements that are not statements of historical fact. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this news release. Each of these forward-looking statements involves risks and uncertainties, many of which are outside of the control of Repare, that could cause the Company's actual results to differ materially from those expressed or implied by the forward-looking statements, including the consummation of the Transaction and the anticipated benefits thereof. Many factors may cause differences between current expectations and actual results, including, but not limited to those related to: (i) the completion of the Transaction on anticipated terms and timing, including obtaining required Court approvals, and the satisfaction of other conditions to the completion of the Transaction; (ii) potential litigation relating to the Transaction that could be instituted by or against the Company, Xeno, XOMA Royalty Corporation or their respective directors or officers, including the effects of any outcomes related thereto; (iii) the risk that disruptions from the Transaction will harm the Company's business, including current plans and operations; (iv) the ability of the Company to retain and hire key personnel; (v) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction; (vi) continued availability of capital and financing and rating agency actions; (vii) legislative, regulatory and economic developments affecting the Company's business; (viii) the accuracy of the Company's financial projections; (ix) general business, market and economic conditions; (x) certain restrictions during the pendency of the Transaction that may impact the Company's ability to pursue certain business opportunities or strategic transactions; (xi) unpredictability and severity of catastrophic events, including but not limited to acts of terrorism, pandemics, outbreaks of war or hostilities, as well as the Company's response to any of the aforementioned factors; (xii) significant transaction costs associated with the Transaction; (xiii) the possibility that the Transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (xiv) competitive responses to the Transaction; and (xv) the risks and uncertainties that are described in the Company's definitive proxy statement on Schedule 14A in respect of the Transaction (the "Proxy Statement"), which is available on the Company's EDGAR and SEDAR+ profiles and as otherwise disclosed from time to time on the Company's EDGAR and SEDAR+ profiles. While the list of factors presented here and in the Proxy Statement is considered representative, no such list should be considered a complete statement of all potential risks and uncertainties related to the Transaction.

Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this news release are identified in the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (the "SEC") and the Autorité des Marchés Financiers (Quebec) ("AMF") on March 3, 2025, and in other filings made with the SEC and AMF from time to time, including the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit reparerx.com and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at <u>https://www.linkedin.com/company/repare-therapeutics/</u>.

**Investor Relations & Media Contact:** 

Matthew DeYoung

Investor Relations and Media

Argot Partners

<u>investor@reparerx.com</u>